PMID- 20586853
OWN - NLM
STAT- MEDLINE
DCOM- 20101027
LR  - 20151119
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 25 Suppl 1
DP  - 2010 May
TI  - Observational comparative trial of the efficacy of proton pump inhibitors versus 
      histamine-2 receptor antagonists for uninvestigated dyspepsia.
PG  - S122-8
LID - 10.1111/j.1440-1746.2009.06218.x [doi]
AB  - BACKGROUND AND AIMS: It is still controversial which drugs, proton pump 
      inhibitors (PPI) or histamine-2 receptor antagonists (H2RA), are more effective 
      for dyspepsia in the Japanese population. METHODS: Patients with uninvestigated 
      dyspepsia (n = 104; male/female 41/63) were treated with either rabeprazole 10 mg 
      o.d. (n = 62) or lafutidine 10 mg b.i.d. (n = 42) for 4 weeks. Questionnaires 
      (modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease 
      [mFSSG] and quality of life [QOL], SF-8) were administered before and after 
      therapy. The mFSSG was classified into a total score (Q-T), reflux score (Q-R), 
      dyspepsia score (Q-D) and pain score (Q-P). The SF-8 had a physical component 
      summary (PCS) and mental component summary (MCS). The predominant type of symptom 
      was reflux (R-S), pain (P-S) or dysmotility (D-S). RESULTS: R-S was 19.2%, P-S 
      48.1%, D-S 24.0% and overlap 8.7%. In the R-S, Q-T and Q-R significantly improved 
      with rabeprazole, but neither scale improved with lafutidine. MCS significantly 
      improved with rabeprazole. In P-S, Q-T, Q-R, Q-D and Q-P significantly improved 
      with both drugs. PCS significantly improved with both, whereas the MCS 
      significant improved with rabeprazole. In D-S, Q-R and Q-D significant improved 
      with rabeprazole, but neither improved with lafutidine. QOL did not improve with 
      either. With overlap, neither scale nor the QOL reached a significant difference. 
      CONCLUSION: Both PPI and H2RA have a positive effect on P-S, but H(2)RA therapy 
      is limited for R-S and D-S, whereas PPI therapy is generally effective. 
      Therefore, careful prescription based on symptoms is important.
FAU - Nagahara, Akihito
AU  - Nagahara A
AD  - Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, 
      Japan. nagahara@juntendo.ac.jp
FAU - Asaoka, Daisuke
AU  - Asaoka D
FAU - Hojo, Mariko
AU  - Hojo M
FAU - Oguro, Masako
AU  - Oguro M
FAU - Shimada, Yuji
AU  - Shimada Y
FAU - Ishikawa, Dai
AU  - Ishikawa D
FAU - Osada, Taro
AU  - Osada T
FAU - Kawabe, Masato
AU  - Kawabe M
FAU - Yoshizawa, Takashi
AU  - Yoshizawa T
FAU - Otaka, Michiro
AU  - Otaka M
FAU - Watanabe, Sumio
AU  - Watanabe S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Acetamides)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Piperidines)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Pyridines)
RN  - 32828355LL (Rabeprazole)
RN  - 49S4O7ADLC (lafutidine)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Acetamides/*therapeutic use
MH  - Adult
MH  - Dyspepsia/complications/*drug therapy
MH  - Esophageal Motility Disorders/drug therapy/etiology
MH  - Female
MH  - Gastroesophageal Reflux/drug therapy/etiology
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Pain/drug therapy/etiology
MH  - Pain Measurement
MH  - Piperidines/*therapeutic use
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Pyridines/*therapeutic use
MH  - Rabeprazole
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2010/07/14 06:00
MHDA- 2010/10/28 06:00
CRDT- 2010/07/01 06:00
PHST- 2010/07/01 06:00 [entrez]
PHST- 2010/07/14 06:00 [pubmed]
PHST- 2010/10/28 06:00 [medline]
AID - JGH6218 [pii]
AID - 10.1111/j.1440-1746.2009.06218.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S122-8. doi: 
      10.1111/j.1440-1746.2009.06218.x.